Skip to main content

Cardiovascular Risk

For the reconstructive urologist, perioperative cardiovascular management is driven by one reality: the operations we do are mostly intermediate-risk — radical cystectomy, open nephrectomy, major pelvic reconstruction, open radical prostatectomy — and the patients are often older with comorbid disease. Perioperative cardiovascular complications occur in ~3% of all noncardiac surgery hospitalizations, and myocardial injury after noncardiac surgery (MINS) — an asymptomatic postoperative troponin elevation — occurs in up to 20% of patients, with 10% 30-day mortality in the highest-risk strata.[3][4] The practical challenge is deciding who to evaluate more, who to medically optimize, and who can simply proceed.

This article consolidates the 2024 AHA/ACC Perioperative Guideline — the single most useful document for this decision — with application to GU reconstructive practice.

See also: Risk Calculators, Antithrombotic Therapy (DAPT and coronary stent management), Frailty.

Stepwise Approach (2024 AHA/ACC)​

The guideline lays out a 5-step algorithm for every patient considered for elective noncardiac surgery:[4]

  1. Determine surgical urgency.
  2. Identify active cardiac conditions (contraindications to elective surgery).
  3. Estimate perioperative MACE risk using a validated calculator.
  4. Assess functional capacity.
  5. Determine need for additional testing — only if results will change management.

Step 1 — Surgical Urgency​

CategoryDefinition
EmergencyImmediate threat to life/limb; <2 h for evaluation
UrgentThreat to life/limb; 2–24 h for evaluation
Time-sensitiveMay delay up to 3 months without harming outcomes
ElectiveCan be delayed for complete evaluation

Urgency overrides everything below — an emergency operation proceeds regardless of cardiac risk score.

Step 2 — Active Cardiac Conditions (Relative Contraindications to Elective Surgery)​

Defer and address before elective surgery:[3][4]

  • Acute coronary syndrome (STEMI, NSTEMI, unstable angina)
  • Acute decompensated heart failure
  • Symptomatic severe aortic stenosis (mean gradient >40 mmHg or peak velocity >4 m/s)
  • Significant arrhythmias with hemodynamic instability (high-grade AV block, sustained VT, symptomatic bradycardia, atrial fibrillation with RVR)
  • Severe hypertrophic cardiomyopathy (symptomatic or with severe LVOT obstruction)

Surgical Risk Categories​

The 2024 AHA/ACC guideline stratifies procedures by expected MACE incidence:[3][4]

RiskMACE incidenceRepresentative procedures
Low<1%Cataract, breast, cosmetic, endoscopic, cystoscopy, TURP/HoLEP, TURBT, minor scrotal/penile surgery
Intermediate1–5%Most genitourinary / general abdominal / orthopedic / ENT — radical cystectomy, open nephrectomy, RARP, major urethroplasty, ureteral reconstruction, augmentation cystoplasty
High>5%Vascular (7.7%), thoracic (6.5%), transplant (6.2%), neurosurgery

Key operative facts for urology:

  • MIS reduces risk — robotic/laparoscopic nephrectomy and prostatectomy are lower-risk than their open counterparts.
  • Emergency surgery carries higher risk than elective at every category.
  • Radical cystectomy is the highest-MACE-incidence routine urologic operation — a true intermediate-risk case that trends toward high-risk in the elderly oncology patient.

Risk Calculators​

Revised Cardiac Risk Index (RCRI)​

The workhorse. Six equally-weighted variables, one point each:

  1. High-risk surgery (intraperitoneal, intrathoracic, suprainguinal vascular)
  2. Ischemic heart disease
  3. Congestive heart failure
  4. Cerebrovascular disease
  5. Insulin-dependent diabetes
  6. Preoperative serum creatinine >2.0 mg/dL

Risk of 30-day MACE (MI, cardiac arrest, death):[1][2][3]

RCRI scoreMACE risk
0~0.4% (up to 0.5% in 9,519-patient cohort[2])
1~1%
2~2.4%
≥3~10%

Limitations: modest discrimination (AUC 0.75), worse in vascular surgery (AUC 0.64).[3]

Alternative Calculators​

  • ACS-NSQIP MICA (Gupta) Calculator — 5 variables; surgical risk by CPT; superior discrimination to RCRI.
  • ACS-NSQIP Universal Surgical Risk Calculator — 21 variables; CPT-specific.
  • AUB-HAS2 — 6 variables (age, hemoglobin, heart disease history, angina/dyspnea, vascular surgery, urgency).[4][5]

In GU practice, NSQIP calculators perform better than RCRI because they incorporate procedure-specific risk via CPT codes.

Functional Capacity​

Metabolic-equivalent (MET) thresholds drive testing decisions:[3]

METsEquivalent activityImplication
≥10Strenuous sports, competitive cyclingVery low perioperative risk regardless of clinical factors
4–10Climb 2 flights of stairs, walk up a hill, heavy housework, moderate cyclingAdequate — generally proceed without further cardiac testing
<4Can't walk 2 blocks on level ground, can't climb a flight of stairsIndependent 2-fold risk increase — consider further testing if it will change management

Practical point: a structured patient interview ("Can you climb a flight of stairs without stopping? Walk 4 blocks at normal pace?") is more useful than pretending to calculate METs. The DASI (Duke Activity Status Index) is validated if you want a formal score.

Excellent functional capacity (>10 METs) effectively rules out most perioperative cardiac concerns independent of RCRI.

Preoperative Cardiac Testing​

General rule: cardiovascular testing is rarely indicated in low-risk patients, and in high-risk patients with good functional capacity.[3][4] Test only if the result will change management.

12-Lead ECG​

Reasonable preoperatively in:[3]

  • Known CAD, arrhythmia, PAD, cerebrovascular disease, structural heart disease
  • Undergoing elevated-risk surgery
  • To establish a baseline for postoperative comparison

ST-segment depression >0.5 mm on preoperative ECG is associated with a 4-fold increase in perioperative MACE (11.2% vs 2.6%).[3]

Routine ECG is not indicated in low-risk patients without cardiac history.

Echocardiography​

Reserved for:[6][7]

  • Suspected moderate or greater valvular disease
  • Suspected significant LV dysfunction or cardiomyopathy
  • High-risk surgery + known heart disease where echo will change management

Not indicated for routine preoperative evaluation of low-risk patients.

Stress Testing​

Not indicated:[3][4]

  • Low-risk patients
  • Patients with excellent functional capacity (≥4 METs)

May be considered only when all of the following apply:

  • Poor functional capacity (<4 METs)
  • Elevated MACE risk (≥1% by calculator)
  • Result would change perioperative management

Options: exercise ECG, dobutamine stress echocardiography, nuclear perfusion imaging, stress CMR.

Coronary Angiography​

Not routinely indicated before noncardiac surgery. Consider only if stress testing shows significant ischemia and revascularization would be pursued regardless of the upcoming noncardiac operation.

Preoperative Biomarkers​

BNP / NT-proBNP — Class IIa Recommendation​

Reasonable to measure preoperatively in:[3][4]

  • Known CVD
  • Age ≥65
  • Age ≥45 with CV symptoms
  • Undergoing elevated-risk surgery

Elevated thresholds (BNP >92 pg/mL or NT-proBNP >300 pg/mL) are associated with a 4-fold increase in 30-day death / MI (21.8% vs 4.9%).[3] Adds 18% to risk reclassification beyond the RCRI.

Cardiac Troponin — Class IIb​

May be reasonable preoperatively to establish a baseline that informs postoperative MINS surveillance.[3][4] No established management strategy for an isolated elevated preoperative troponin.

Perioperative Medical Therapy​

Statins — Continue (Class I)​

  • Continue existing statins through the perioperative period.[4]
  • Initiate in statin-naive patients who meet criteria for chronic statin therapy (ASCVD history, qualifying 10-year risk) — ideally before elective surgery.[4]
  • Observational data associate perioperative statin use with lower mortality (1.8% vs 2.3%).[3]

Beta-Blockers — Continue (Class I), Do NOT Initiate on Day of Surgery (Class III, Harm)​

  • Continue chronic beta-blockers — withdrawal triggers rebound tachycardia and ischemia.[4]
  • New initiation (if indicated for another reason): start at least 7 days before elective surgery and titrate to avoid hypotension/bradycardia (Class IIb).[4]
  • Do NOT start on day of surgery — POISE-1 and subsequent data show increased stroke (1.0% vs 0.5%) and mortality (3.1% vs 2.3%).[3][4]

Aspirin — Not Routinely Recommended for CV Protection​

  • POISE-2 showed routine perioperative aspirin did not reduce cardiovascular events and increased major bleeding (4.6% vs 3.8%).[3]
  • Continue aspirin when ischemic risks outweigh bleed risks — particularly recent coronary stents (see below).

ACE Inhibitors / ARBs​

  • 2024 guideline: reasonable to hold on the morning of surgery to avoid intraoperative hypotension.
  • Restart within 48 h postoperatively if renal and hemodynamic status allow.

SGLT2 Inhibitors — Hold 3–4 Days Before Surgery​

Stop 3–4 days preoperatively to prevent euglycemic ketoacidosis, which is a documented perioperative complication of SGLT2 inhibitor continuation through major surgery.[8]

Antithrombotic Management​

See Antithrombotic Therapy for DOAC hold times, bridging, and reversal. Key points for cardiac indications:

  • Atrial fibrillation — bridge only mechanical valve or prior stroke/recent VTE (BRIDGE trial).
  • Coronary stent — see below.

Coronary Stents and Elective Surgery​

Patients with recent coronary stents are at ~6-fold increased risk of perioperative MACE (8.9% vs 1.5% without stents).[3] Elective surgery timing:[4]

Stent / indicationMinimum elective-surgery delay
Bare-metal stent (BMS)≥30 days
Drug-eluting stent (DES) — stable CCD indication≥6 months (ideally 12)
Drug-eluting stent (DES) — ACS indication≥12 months
Time-sensitive within DES window≥3 months (DES, CCD) with cardiology / surgery shared decision

Antiplatelet management around surgery:[4]

  • Continue aspirin 75–100 mg through surgery whenever feasible (Class I).
  • Continue DAPT if within obligatory windows (BMS <30 days, DES <3–12 months depending on indication) unless the bleed risk is catastrophic (intracranial, posterior chamber ophthalmologic).
  • Cardiology consultation before any operation that would require stopping DAPT inside the high-risk window.

Valvular Heart Disease​

Aortic Stenosis​

  • Symptomatic severe AS — contraindication to elective noncardiac surgery; consider AVR or TAVR first.[7]
  • Asymptomatic severe AS with normal LVEF — noncardiac surgery can proceed with acceptable risk and careful intraoperative hemodynamic management.
  • Heart-team consultation for severe VHD + elevated-risk noncardiac surgery.

Mitral Stenosis​

  • Maintain preload and sinus rhythm.
  • Avoid tachycardia (shortened diastolic filling).
  • PASP >50 mmHg is a significant risk escalator.

Regurgitant Lesions​

  • Generally better tolerated than stenotic lesions.
  • Avoid increased afterload and bradycardia.
  • Consider valve intervention before elective noncardiac surgery if standard guideline indications for valve surgery are met.

Cardiac Implantable Electronic Devices (CIEDs)​

Pacemakers​

  • Confirm dependency and device type preoperatively.
  • For electrocautery use within 6 inches of generator (most abdominal and pelvic surgery): switch to asynchronous mode (DOO, VOO) to avoid electromagnetic-interference-induced inhibition.
  • Magnet application intraoperatively triggers asynchronous pacing in most modern pacemakers.
  • Monopolar cautery — the worst offender; bipolar is safer.

ICDs​

  • Inhibit anti-tachycardia therapy preoperatively (programming or magnet placement).
  • External defibrillation pads placed at induction.
  • Re-enable ICD before discharge from PACU / before ambulation.

Urologic-Specific Considerations​

  • TURP / HoLEP monopolar cautery near the pelvis — same CIED precautions as abdominal surgery.
  • Ureteral stent placement and percutaneous nephrostomy under fluoroscopy — minimal EMI risk, but pacemaker function should still be confirmed.

Myocardial Injury After Noncardiac Surgery (MINS)​

Definition: postoperative troponin elevation above the 99th percentile of presumed ischemic origin — without required symptoms.[4][9][10]

Epidemiology​

  • Occurs in ~20% of patients undergoing noncardiac surgery.
  • 30-day mortality ~10% overall; 17% in highest troponin quartile vs 1% in lowest.
  • 80–90% are asymptomatic — the reason for surveillance, not symptom-triggered testing.

Surveillance — Class IIb​

Reasonable to measure troponin at 24 and 48 h postoperatively in:[4][9]

  • Known CVD
  • Age ≥65 with CV risk factors
  • Elevated-risk surgery

Management​

  • Outpatient cardiology follow-up for risk-factor optimization (Class IIa).[4][10]
  • Consider initiation/intensification of statin, aspirin (if no bleeding contraindication), ACE inhibitor, beta-blocker.
  • Antithrombotic therapy may be considered (Class IIb).
  • Cardiology consultation is associated with reduced 30-day mortality in observational series.

GU-Specific Perioperative Cardiovascular Considerations​

  • Radical cystectomy is the urologic operation with the highest 30-day MACE rate; apply the full AHA/ACC workup including preoperative BNP/NT-proBNP and consider 24/48 h postoperative troponin in at-risk patients.
  • Elderly elective reconstructive work (posterior urethroplasty, open sling revision, AUS in older men) — functional capacity assessment is often the highest-yield single step.
  • Post-radiation pelvic reconstruction patients often have coronary artery disease from the same atherosclerotic risk factors that drove their original cancer-related evaluation; threshold for preop ECG / BNP is low.
  • Renal function — many urologic patients have CKD that drives both surgical risk (stent-placement bleed profile, contrast load for preop imaging) and medication choices (ACE/ARB, metformin, DOAC dosing).
  • Intraoperative Trendelenburg + CO2 insufflation (robotic pelvic surgery) — large preload/afterload shifts; patients with severe AS or systolic dysfunction need echo-informed hemodynamic planning.

Key Recommendations at a Glance​

RecommendationClass
Focused history, physical exam, functional capacity assessment for every patientI
Use validated risk calculator (RCRI or NSQIP) for patients with known CVDIIa
Continue statins perioperativelyI
Continue chronic beta-blockers perioperativelyI
Do NOT start beta-blocker on the day of surgeryIII — Harm
Stress testing only if result will change managementIIa/IIb
Preoperative BNP/NT-proBNP in elevated-risk patients (age ≥65, known CVD, elevated-risk surgery)IIa
Delay elective surgery ≥30 days after BMS, ≥6–12 months after DESI / IIb
Continue aspirin 75–100 mg in patients with coronary stents whenever feasibleI
Postoperative troponin surveillance at 24/48 h in at-risk patientsIIb
Routine perioperative aspirin NOT recommended for CV protection (POISE-2)III
Hold SGLT2 inhibitor 3–4 days before major surgeryIIa

References​

1. Duceppe E, Parlow J, MacDonald P, et al. "Canadian Cardiovascular Society Guidelines on Perioperative Cardiac Risk Assessment and Management for Patients Who Undergo Noncardiac Surgery." Can J Cardiol. 2017;33(1):17–32. doi:10.1016/j.cjca.2016.09.008

2. Davis C, Tait G, Carroll J, Wijeysundera DN, Beattie WS. "The Revised Cardiac Risk Index in the New Millennium — 9,519 Consecutive Elective Surgical Patients." Can J Anaesth. 2013;60(9):855–63. doi:10.1007/s12630-013-9988-5

3. Smilowitz NR, Berger JS. "Perioperative Cardiovascular Risk Assessment and Management for Noncardiac Surgery: A Review." JAMA. 2020;324(3):279–290. doi:10.1001/jama.2020.7840

4. Thompson A, Fleischmann KE, Smilowitz NR, et al. "2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery." J Am Coll Cardiol. 2024;84(19):1869–1969. doi:10.1016/j.jacc.2024.06.013

5. Patel AY, Eagle KA, Vaishnava P. "Cardiac Risk of Noncardiac Surgery." J Am Coll Cardiol. 2015;66(19):2140–2148. doi:10.1016/j.jacc.2015.09.026

6. Doherty JU, Daugherty SL, Kort S, et al. "ACC/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2024 Appropriate Use Criteria for Multimodality Imaging in Cardiovascular Evaluation of Patients Undergoing Nonemergent, Noncardiac Surgery." J Am Coll Cardiol. 2024;84(15):1455–1491. doi:10.1016/j.jacc.2024.07.022

7. Otto CM, Nishimura RA, Bonow RO, et al. "2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease." J Am Coll Cardiol. 2021;77(4):e25–e197. doi:10.1016/j.jacc.2020.11.018

8. Bhave NM, Cibotti-Sun M, Moore MM. "2024 Perioperative Cardiovascular Management for Noncardiac Surgery Guideline-at-a-Glance." J Am Coll Cardiol. 2024;84(19):1970–1975. doi:10.1016/j.jacc.2024.08.018

9. Devereaux PJ, Szczeklik W. "Myocardial Injury After Non-Cardiac Surgery: Diagnosis and Management." Eur Heart J. 2020;41(32):3083–3091. doi:10.1093/eurheartj/ehz301

10. Ruetzler K, Smilowitz NR, Berger JS, et al. "Diagnosis and Management of Patients With Myocardial Injury After Noncardiac Surgery: A Scientific Statement From the American Heart Association." Circulation. 2021;144(19):e287–e305. doi:10.1161/CIR.0000000000001024